26th International Prostate Cancer Update (IPCU 26)
In conjunction with the Medical College of Wisconsin (MCW), Carden Jennings Publishing Co., Ltd. (CJP) proposes to develop a live conference on the topic of prostate cancer. This conference will encompass expert lectures, interactive discussions, a panel roundtable, debates, and case reports. It will be physician-led, multi-supported, and designed for urologists, medical oncologists, and other healthcare professionals involved in the treatment of prostate cancer.
The 26th International Prostate Cancer Update (IPCU 26), being held January 20-23, 2016, in Vail Colorado, will be a Sunshine-exempt, CME-accredited educational program. As such, it will meet the following requirements: (1) the provider and program is accredited, (2) no direct payments are allowed between CME supporters and physician faculty, and (3) CME supporters have no role in directing, suggesting, or implementing how the proceeds of the grant are used by the CME provider.
The goal of this educational program is to equip urologists, medical oncologists, and other healthcare professionals involved in the treatment of prostate cancer with the up-to-date clinical knowledge and tools they need to best treat their patients.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Medical College of Wisconsin and Carden Jennings Publishing. The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians.
The Medical College of Wisconsin designates this live activity for a maximum of 23 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been developed and is intended for urologists, medical oncologists, radiation oncologists and other healthcare professionals involved in the treatment of prostate cancer.
- Evaluate the use of biomarkers in prostate cancer detection
- Compare imaging and other advanced technologies in treating localized prostate cancer
- Integrate available hormonal, cytotoxic, and immunotherapeutic agents for advanced and castration-resistant prostate cancer
- Asess the options for personalizing treatment and sequencing new therapies in individual patients
- Discuss how to incorporate the treatment of prostate cancer into overall men's health
Disclosure information provided on-site.
In accordance with the ACCME standards for commercial support number 6, all in control of content disclosed any relevant financial relationships. These relatinoships were reviewed via the MCW conflict of interest resolution process and resolved.
- 15.00 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 15.00 Hours of ParticipationHours of Participation credit.